Ignite Creation Date:
2024-05-05 @ 9:36 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00000996
Status:
COMPLETED
Last Update Posted:
2021-11-04
First Post:
1999-11-02
Brief Title:
A Study of Doxorubicin in the Treatment of AIDS-Related Kaposis Sarcoma
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
Phase II Study of Weekly Doxorubicin Treatment of AIDS Associated Kaposis Sarcoma
Status:
COMPLETED
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To study the natural course of AIDS related Kaposis sarcoma and to determine the usefulness and safety of weekly administration of small doses of doxorubicin
Doxorubicin is one of the most active of all antitumor agents but at currently used doses toxicity is common When small doses are administered on a weekly schedule the toxicity of the drug appears to be reduced
Doxorubicin is one of the most active of all antitumor agents but at currently used doses toxicity is common When small doses are administered on a weekly schedule the toxicity of the drug appears to be reduced
Detailed Description:
Doxorubicin is one of the most active of all antitumor agents but at currently used doses toxicity is common When small doses are administered on a weekly schedule the toxicity of the drug appears to be reduced
Patients are stratified for non-therapy purposes into 2 groups doxorubicin is given intravenously IV every week on an outpatient basis Patients are monitored carefully and weekly blood samples are taken to determine the effectiveness and safety of treatment Patients are evaluated for toxicity after one dose of the drug and weekly thereafter Patients are evaluated for response to the drug after 4 weeks and monthly thereafter
Patients are stratified for non-therapy purposes into 2 groups doxorubicin is given intravenously IV every week on an outpatient basis Patients are monitored carefully and weekly blood samples are taken to determine the effectiveness and safety of treatment Patients are evaluated for toxicity after one dose of the drug and weekly thereafter Patients are evaluated for response to the drug after 4 weeks and monthly thereafter
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 10982 | REGISTRY | DAIDS ES Registry Number | None |